NASDAQ Biotechnology Index

(redirected from NASDAQ Biotech Index)
Also found in: Wikipedia.

NASDAQ Biotechnology Index

An index tracking pharmaceutical, biological research and similar companies whose shares trade on NASDAQ. It is weighted under a modified market capitalization scheme; the securities that compose it are updated semi-annually.
References in periodicals archive ?
The Nasdaq Biotech Index saw five pullbacks of more than 6.
Biotech stocks, as measured by the Nasdaq Biotech Index (NBI), have risen 50% over the past year, in part due to a spate of mergers and acquisitions as big pharmaceutical companies seek to bolster their pipelines of experimental drugs.
The Nasdaq Biotech Index includes companies classified under the Financial Times Stock Exchange's global system as either biotechnology or pharmaceutical.
The Biotechnology Industry Organization reports that the Nasdaq biotech index surged 46% in 2003, helping biotech companies amass $16.
After the March 13 announcement to that effect by President Bill Clinton and British Prime Minister Tony Blair, the NASDAQ Biotech Index lost one-eighth of its value in two days.
The Nasdaq Biotech Index (NBI) is up 27% year-to-date, beating the S&P 500 by a factor of 3.
With just one trading day left in March, the Nasdaq biotech index was down about 13 per cent for the month at Friday's close.
Overall, the Nasdaq Biotech Index plummeted 12 percent.
Biotechnology: Between 1992 and 1995, the Nasdaq biotech index fell by 70%.
BOSTON -- EvaluatePharma([R]), the premier source for pharmaceutical and biotechnology sector analysis and consensus forecasts, today released a report, titled "Surveying Tomorrow's BioPharma Landscape: The NASDAQ Biotech Index Up Close," which shows that the quantity of biologic drugs on the market will likely soar by 2018.
The fund has outperformed its benchmark, the NASDAQ Biotech Index, by 7.